Skip to main content
syn
Daily Digest

Definium's LSD-based pill reduces anxiety in study

Published Thursday, August 13, 2026 · Updated August 13

Share on X

Narrative Spectrum

Convergent Narrative · 0
  • Single-Source Coverage1 source

What We Know — Key Points

  • Definium Therapeutics' experimental LSD-based pill, DT120, significantly reduced anxiety symptoms in a late-stage study, with patients on the drug experiencing an 11.6-point drop on a standard anxiety rating scale at week 12, compared with a 6.2-point drop for those on a placebo.

What Is Claimed — Perspectives

Single-Source Coverage

AI-Generated Content

  • This topic was generated by an AI system.
  • Key points, perspectives, bias labels, and categorisation may contain errors.
  • This is not journalism. Do not rely on this content for critical decisions.
  • Read our full AI disclaimer for details.